Facial fat volume in HIV-infected patients with lipoatrophy

Antiviral Therapy

Volumn 10, Issue 4, 2005, Pages 575-581

  Yang, Yong ^a   Sitoh, Yih Yian ^b   Tha, Naing Oo ^a   Paton, Nicholas I ^a,c  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE;

ADULT; ARTICLE; BODY FAT; CHEEK; CHEEK MUCOSA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; FACE MUSCLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; ORBIT; PRIORITY JOURNAL; WASTING SYNDROME; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; BODY WEIGHTS AND MEASURES; FACE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 23044443212     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Carr A, Emery S, Law M, Puls R, Lundgren JD & Powderly WG; HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735.
2. Martinez E, Garcia-Viejo MA, Blanch L & Gatell JM. Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Safety 2001; 24:157-166.
3. Collins E, Wagner C & Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader 2000; 10:546-550.
4. Brinkman K, Smeitink JA, Romijn JA & Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
5. Viraben R & Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12:F37-39.
6. Pujol RM, Domingo P, Xavier-Matias-Guiu, Francia E, Sanbeat MA, Alomar A & Vazquez G. HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases. Journal of the American Academy of Dermatology 2000; 42:193-198.
7. Lemieux L, Liu RS & Duncan JS. Hippocampal and cerebellar volumetry in serially acquired MRI volume scans. Magnetic Resonance Imaging 2000; 18:1027-1033.
8. Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne H, Pauchard M, Schoen H, Bousquet R, Katz P, Costagliola D & Katlama C. Polylactic acid implants (new-fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003; 17:2471-2477.
9. Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I & Molina JM. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. Journal of Acquired Immune Deficiency Sydromes 2005; 38:393-398.
10. Talmor M, Hoffman LA & LaTrenta GS. Facial atrophy in HIV-related fat redistribution syndrome: anatomic evaluation and surgical reconstruction. Annals of Plastic Surgery 2002; 49:1 1-7.
11. Stuzin JM, Wagstrom L, Kawamoto HK, Baker TJ & Wolfe SA. The anatomy and clinical applications of the buccal fat pad. Plastic & Reconstructive Surgery 1990; 85:29-37.
12. Kahn JL, Wolfram-Gabel R & Bourjat P. Anatomy and imaging of the deep fat of the face. Clinical Anatomy 2000; 13:373-382.
13. Okamoto K, Ito J, Ishikawa K, Sakai K & Tokiguchi S. Change in signal intensity on MRI of fat in the head of markedly emaciated patients. Neuroradiology 2001; 43:134-138.
14. Paton NI, Macallan DC, Jebb SA, Noble C, Baldwin C, Pazianas M & Griffin GE. Longitudinal changes in body composition measured with a variety of methods in patients with AIDS. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1997; 14:119-127.
15. Cavalcanti MG, Rocha SS & Vannier MW. Craniofacial measurements based on 3D-CT volume rendering: implications for clinical applications. Dento Maxillo Facial Radiology 2004; 33:170-176.
16. Padilla S, Gallego JA, Masia M & Gutierrez E. Single-slice computed tomography and anthropometric skinfold analysis for evaluation of facial lipoatrophy in HIV-infected patients. Clinical Infectious Diseases 2004; 39:1848-1851.
17. Martinez E, Bianchi L, Garcia-Viejo MA, Bru C & Gatell JM. Sonographic assessment of regional fat in HIV-1-infected people. Lancet 2000; 356:1412-1413.
18. Guaraldi G, Orlando G, De Fazio D, Grisotti A, Borghi V, Nardini G, Beghetto B & Esposito R. Long-term follow-up of graft hypertrophy after autologous fat transfer for HIV-related face lipoatrophy (hamster syndrome 1 year later). 6th International Workshop on Adverse Drug Reactions & Lipodystrophy in HIV. 25-28 October 2004, Washington, DC, USA. Abstract 90.
19. D Carey, H Wand, A Martin, S Emery, A Carr, D Cooper & the ROSEY Study Group., Evaluation of ultrasound for assessing facial lipoatrophy in a andomized, placebo-controlled trial. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, USA. Abstract 727.
20. Benn P, Ruff C, Cartledge J, Sauret V, Copas A, Linney A, Williams IG, Smith C & Edwards SG. Overcoming subjectivity in assessing facial lipoatrophy: is there a role for three-dimensional laser scans? HIV Medicine 2003; 4:325-331.
21. Yang Y & Paton NI. Laser scanning as a tool for assessment of HIV-related facial lipoatrophy: evaluation of accuracy and reproducibility. HIV Medicine: in press.